Clinical Trial Update: Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating sitagliptin to prevent new-onset diabetes after kidney transplantation; study terminated with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Sitagliptin (sitagliptin)

Snippet

Sponsor: University of Nebraska | Conditions: Type 2 Diabetes, End Stage Renal Disease | Phase 4 | Status: TERMINATED | Results posted: 2018-04-24